PTC/SB/08s (08-03.)
Approved for use through 07/31/2006, OMB 0651-0031
U.S. Patient and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Us Pieters and Transport of the Properties of th

Filing Date

STATEMENT BY APPLICANT			First I	First Named Inventor Masako NOMOTO								
			Art U	Art Unit								
( Not for submission under 37 CFR 1.99)					Examiner Name							_
					Attorney Docket Numb		er	KAN-114US				
				_								
					U.S.	PATENTS				Remove		
Examiner Initial*	Cite No	Patent Number	Patent Number Kind Code <sup>1</sup>				of sited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear			
	1	6523025		2003-02-18		Hashimoto et al.						
	2	6205456		2001-0	3-20	Nakao						
If you wish	h to a	i dd additional U.S. Pate	nt citatio	n inform	ation pl	ease click	the A	dd button.		Add		
			U.S.P	ATENT	APPLI	CATION P	UBLI	CATIONS		Remove		-
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publica Date	cation Name of Patentee or Applicant Rele			Releva	es,Columns,Lines where evant Passages or Relevant ures Appear			
	1											
If you wish	h to a	l dd additional U.S. Publ	ished Ap	olication	n citatio	l n informati	on ple	ease click the Ad	d button	Add		_
				FORE	GN PAT	ENT DOC	UME	NTS		Remove		_
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>		Kind Code <sup>4</sup>		on /	Applicant of cited wh		where Rel	or Relevant	T6
	1	JP2003-157254	JP	Р		2003-05-3	80	JUST SYST CORE	,			
	2 JP2003-157271 JP			2003-05-3	003-05-30 MITSUBISHI ELECTRIC CORP							

	Application Number		
	Filing Date		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor	Masa	ako NOMOTO
( Not for submission under 37 CFR 1.99)	Art Unit		
,	Examiner Name		
	Attorney Docket Numb	er	KAN-114US

	3	JP 1	1-259498	JP		1999-09-24	FUJITSU LTD.		
If you wis	h to a	dd add	litional Foreign F	Patent Document	citation	information p	lease click the Add butt	on Add	
				NON-PATE	NT LITE	ERATURE DO	CUMENTS	Remove	
Examiner Initials*	Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.							Τs	
International Search Report for Application No. PCTI/IP20050008317, dated May 17, 2005									
If you wis	h to a	dd add	fitional non-pater	nt literature docu	ment ci	tation informat	ion please click the Add	button Add	
				EX	AMINE	R SIGNATUR	Έ		
Examiner	Signa	ature					Date Considered		

See Kind Codes of USPTO Patent Documents at xwex\_USPTO\_CODV or MPEP 961.04. Enter office that assed the document, by the Noveleton (WIPO Standard ST3.). For Lapsanese patent document, the articulation of the year of the right or the Emperor warp rescess the sent annumber of the patent document.

\*\*And of Gourrent by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. \*\*Applicant is to place a check mark here if Emploits around the service of the sent annumber of the service of the servi

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

# Application Number Filing Date Filing Date

### CERTIFICATION STATEMENT

Diagea coa	37 CEE	2 1 97 au	nd 1 98 to	make the	annronniato	selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 3.7 CFR 197(eV1).

# OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 155(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1976(c)

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- 7 None

### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Lawrence E. Ashery/	Date (YYYY-MM-DD)	2006-09-29
Name/Print	Lawrence E. Ashery	Registration Number	34515

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fand by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C.12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patient and Tradenant's Office, U.S. operationed for Commence, P. 0. Bot 1450, Alexandria, V.S.231.1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.2.231.1450.

# Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is \$3 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
  - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2504 and 2506. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the state of the s
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.